Altimmune Inc (ALT)
7.16
-0.11
(-1.51%)
USD |
NASDAQ |
May 08, 16:00
6.91
-0.25
(-3.49%)
After-Hours: 20:00
Altimmune Enterprise Value: 309.80M for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 08, 2024 | 309.80M |
May 07, 2024 | 317.59M |
May 06, 2024 | 323.97M |
May 03, 2024 | 319.72M |
May 02, 2024 | 311.92M |
May 01, 2024 | 303.41M |
April 30, 2024 | 266.55M |
April 29, 2024 | 255.56M |
April 26, 2024 | 316.88M |
April 25, 2024 | 312.63M |
April 24, 2024 | 304.12M |
April 23, 2024 | 338.86M |
April 22, 2024 | 331.77M |
April 19, 2024 | 292.07M |
April 18, 2024 | 290.65M |
April 17, 2024 | 301.29M |
April 16, 2024 | 335.32M |
April 15, 2024 | 337.44M |
April 12, 2024 | 368.64M |
April 11, 2024 | 397.71M |
April 10, 2024 | 370.06M |
April 09, 2024 | 397.71M |
April 08, 2024 | 412.59M |
April 05, 2024 | 446.62M |
April 04, 2024 | 433.15M |
Date | Value |
---|---|
April 03, 2024 | 460.80M |
April 02, 2024 | 465.41M |
April 01, 2024 | 527.44M |
March 28, 2024 | 523.90M |
March 27, 2024 | 432.44M |
March 26, 2024 | 415.43M |
March 25, 2024 | 406.92M |
March 22, 2024 | 445.91M |
March 21, 2024 | 446.06M |
March 20, 2024 | 462.31M |
March 19, 2024 | 419.91M |
March 18, 2024 | 443.94M |
March 15, 2024 | 499.06M |
March 14, 2024 | 510.73M |
March 13, 2024 | 573.28M |
March 12, 2024 | 570.45M |
March 11, 2024 | 499.77M |
March 08, 2024 | 536.52M |
March 07, 2024 | 511.08M |
March 06, 2024 | 607.20M |
March 05, 2024 | 596.60M |
March 04, 2024 | 583.17M |
March 01, 2024 | 656.67M |
February 29, 2024 | 657.38M |
February 28, 2024 | 740.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-33.51M
Minimum
Aug 25 2023
984.81M
Maximum
Jul 20 2020
211.85M
Average
168.91M
Median
Aug 04 2021
Enterprise Value Benchmarks
Eli Lilly and Co | 760.27B |
Amgen Inc | 219.16B |
Pfizer Inc | 217.25B |
Viking Therapeutics Inc | 7.849B |
Precision BioSciences Inc | -16.32M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -31.64M |
Revenue (Quarterly) | 0.037M |
Total Expenses (Quarterly) | 21.24M |
EPS Diluted (Quarterly) | -0.56 |
Profit Margin (Quarterly) | -85.52K% |
Earnings Yield | -23.32% |
Normalized Earnings Yield | -23.32 |